CM336 for Autoimmune Blistering Disease
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new drug called CM336 for people with autoimmune blistering diseases. The drug is designed to calm the immune system and reduce blistering, aiming to improve skin health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of an autoimmune blistering disease (like pemphigus or bullous pemphigoid).
- You are 18 years old or older.
- You have not been treated with a drug that targets BCMA (a protein on immune cells).
- You are not allergic to monoclonal antibody drugs or any ingredient in the study drug CM336.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
This trial tests a new treatment called OM336 for people with active autoimmune diseases that have not improved after at least two other treatments. The goal is to see if OM336 can help control the disease.
This study tests a new drug, CM313, for people with moderate to severe pemphigus (a blistering skin disease). It aims to see if the drug can help heal the blisters and sores.
This study tests CM336, a new type of immunotherapy drug, for patients with multiple myeloma (a blood cancer) that has come back or progressed after their first treatment. The trial aims to see if this drug can help control the disease in patients at high risk of relapse.
This study tests a new drug called CM336 for people with primary Sjögren's syndrome (an autoimmune disease affecting salivary and tear glands). The drug is designed to help reduce disease activity in patients who haven't responded well to previous treatments.
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
Hear when a new Autoimmune Bullous Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.